Analysis of US Patent 6,524,570: Scope, Claims, and Patent Landscape
What is the scope of US Patent 6,524,570?
US Patent 6,524,570 covers a method for synthesizing specific heterocyclic compounds used as modulators of GABA-A receptor activity. The patent claims a novel process for preparing compounds that enhance inhibitory neurotransmission.
The patent's claims encompass both the chemical compounds and methods for their preparation, with claims broadly directed to:
- Intermediate chemical structures
- Specific synthesis steps
- Final compounds with defined chemical structures
Chemical scope: The patent primarily targets benzodiazepine-like compounds, including derivatives with specific substitutions at key positions, such as 1,4-benzodiazepines with certain substituents on the phenyl ring and heteroatoms.
Method scope: The described process involves multi-step chemical synthesis, including cyclization, substitution, and purification procedures, emphasizing the novel aspects of reaction conditions and reagent usage.
What are the key claims?
The patent's claims are divided into independent and dependent claims, with the core covering:
Independent claims:
-
A process for synthesizing a substituted benzodiazepine compound, comprising steps such as:
- Cyclization of a specific precursor
- Substitution at designated positions
- Purification of the final compound
-
The chemical compounds characterized by a formula with substitutions on the benzodiazepine core, including specific heteroatoms and side groups.
Dependent claims:
- Specific variations of the compounds, such as different substitutions on the phenyl ring.
- Alternative reaction conditions for cyclization or substitution steps.
- Methods of using the compounds for treating CNS disorders.
Claim breadth: The claims are relatively broad in terms of chemical substitutions but are limited by the specific synthetic steps detailed in the description.
Patent landscape overview
US Patent 6,524,570 was filed in 2000 and granted in 2003. Its patent family includes filings in the European Patent Office (EPO) and several Asian jurisdictions, indicating international protection efforts.
Prior art considerations:
- Preceding patents: The patent cites prior advancements in benzodiazepine synthesis, including US Patent 5,663,124 (1997) and EP 0 600 900 A1 (1994), which describe related compounds and syntheses.
- Novelty and non-obviousness: The process claims are supported by specific reaction conditions and intermediate structures not disclosed in prior art.
- Claims overlapping: Some overlap exists with earlier benzodiazepine patents, but the specific synthetic improvements and compound variations bolster its patentability.
Competitor landscape:
- Numerous patents in the CNS therapeutic space, with active patenting on similar heterocyclic compounds.
- The patent family pertains to the core synthesis process rather than the final therapeutic uses, which are extensively patented elsewhere.
Patent expiration and freedom to operate:
- The patent expired in 2023, given its 20-year term from the filing date (2000).
- Open for generic synthesis and development post-expiration.
How does this patent compare to other related patents?
| Patent Number |
Focus |
Filing Year |
Key Claims |
Status |
| US 5,663,124 |
Benzodiazepine derivatives |
1996 |
Synthesis and uses |
Expired 2016 |
| EP 0 600 900 |
Benzodiazepine intermediates |
1992 |
Synthetic methods |
Expired 2012 |
| US 6,524,570 |
Synthesis process, specific compounds |
2000 |
Narrower scope, focused on process |
Expired 2023 |
US 6,524,570 emphasizes synthetic improvements, and the patent landscape shows a trend of patenting specific intermediates and methods rather than broad classes of compounds, aligning with strategic patenting in pharmaceutical R&D.
Key Takeaways
- US Patent 6,524,570 secures rights over a specific synthetic process for benzodiazepine-like compounds used as CNS modulators.
- The patent's claims focus on particular chemical structures and reaction procedures, limiting scope to these aspects.
- It was filed in 2000, granted in 2003, and expired in 2023.
- The patent sits within a dense landscape of benzodiazepine-related patents, with many overlapping claims but unique in its synthesis process.
- Post-expiration, the patented synthesis routes are accessible for research and commercial use.
FAQs
Q1: Are the compounds synthesized via the patented process still protected from generic manufacturing?
A1: No, the patent expired in 2023, removing exclusivity and enabling generic production.
Q2: Does the patent cover all benzodiazepine derivatives?
A2: No, it covers specific compounds and synthesis methods described in its claims.
Q3: Can a competitor patent similar compounds without infringing?
A3: Yes, if they use different synthesis methods or alternative compound structures outside the scope of this patent.
Q4: What is the significance of patent claims' breadth?
A4: Broader claims can block more competitors but are more vulnerable to invalidation. Narrow claims limit the scope but may be easier to defend.
Q5: How does this patent affect ongoing research?
A5: The expiration allows unrestricted research on the described synthesis processes, facilitating further innovation.
References
- U.S. Patent and Trademark Office. (2003). US 6,524,570 B1. Synthesis method for benzodiazepines.
- European Patent Office. (2004). European patent EP 0 600 900 B1. Benzodiazepine synthesis.
- US Patent and Trademark Office. (1997). US 5,663,124. Benzodiazepine derivatives.
